Skip to main navigation

Menu

About Us
- Our Team
  - Our Chief Innovator
- Our Network
Technology
Pipeline
MEDIA
Investors
Careers
Get In Touch

News Releases

Year

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 06, 2025

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 30, 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 23, 2025

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Oct 17, 2025

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 07, 2025

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 15, 2025

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 14, 2025

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 31, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 26, 2025

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

Feb 05, 2025

Print Page
Email Alerts
RSS Feeds
Contact IR

Company

About
Careers
Contact

Resources

News
Applications
Technology

San Jose Office

2051 Ringwood Ave. San Jose CA, 95131

© Rani Therapeutics. All Rights Reserved. Rani, Rani Therapeutics, and RaniPill and their corresponding logos are trademarks or registered trademarks of Rani Therapeutics, LLC in the US and other countries.